Cargando…

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics

Detalles Bibliográficos
Autores principales:	Khan, Mohd Wajid Ali, Aziz, Mohammad Azhar, Rajendrasozhan, Saravanan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478216/ https://www.ncbi.nlm.nih.gov/pubmed/37675110 http://dx.doi.org/10.3389/fimmu.2023.1270182

Ejemplares similares

Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
por: Schlicher, Lisa, et al.
Publicado: (2023)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Potential Use of γδ T Cell-Based Vaccines in Cancer Immunotherapy
por: Khan, Mohd Wajid A., et al.
Publicado: (2014)

Editorial: Nanobody-based cancer immunotherapy and immunoimaging
por: Jafari, Mahdie, et al.
Publicado: (2023)

Increased Levels of Autoantibodies against ROS-Modified Proteins in Depressed Individuals with Decrease in Antibodies against SARS-CoV-2 Antigen (S1-RBD)
por: Sherwani, Subuhi, et al.
Publicado: (2022)

Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies
por: Nan, Yanyang, et al.
Publicado: (2023)

Directional preference for glioblastoma cancer cell membrane encapsulated nanoparticle population: A probabilistic approach for cancer therapeutics
por: Khan, Saif, et al.
Publicado: (2023)

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
por: Li, Yueyi, et al.
Publicado: (2023)

Editorial: Adenosine pathways in cancer immunity and immunotherapy
por: Fu, Junjiang, et al.
Publicado: (2023)

Small Molecule-directed Immunotherapy against Recurrent Infection by Mycobacterium tuberculosis
por: Bhattacharya, Debapriya, et al.
Publicado: (2014)

Editorial: Combining chemo/radio therapy and immunotherapy for cancers—perfect mix of old and new
por: Slaney, Clare Y., et al.
Publicado: (2023)

Editorial: “Cancer Immunotherapy: Lights and Shadows”
por: Barrio, María Marcela, et al.
Publicado: (2015)

Editorial: Targeting Metabolism in Cancer Immunotherapy
por: Roszik, Jason, et al.
Publicado: (2018)

Editorial: NKT Cells in Cancer Immunotherapy
por: Webb, Tonya J., et al.
Publicado: (2020)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Editorial: Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II
por: Xu, Caili, et al.
Publicado: (2023)

Editorial: NK Cell-Based Cancer Immunotherapy
por: Borrego, Francisco, et al.
Publicado: (2016)

Erratum: Editorial: NKT Cells in Cancer Immunotherapy
Publicado: (2020)

Editorial: CD4(+) T Cells in Cancer Immunotherapies
por: González-Navajas, José M., et al.
Publicado: (2021)

Editorial: Extracellular traps in cancer immunity and immunotherapy
por: Rahat, Michal A., et al.
Publicado: (2023)

Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
por: Goedegebuure, Ruben S. A., et al.
Publicado: (2019)

Editorial: Influenza Virus Vaccines and Immunotherapies
por: Kumar, Arun, et al.
Publicado: (2015)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
por: Chandra, Janin, et al.
Publicado: (2022)

Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
por: Martin, Francisco, et al.
Publicado: (2022)

Editorial: Targeting glucose metabolism in cancer immunity and immunotherapy
por: Feron, Olivier, et al.
Publicado: (2023)

Editorial: Novel biomarkers for predicting response to cancer immunotherapy
por: Huangfu, Shuchen, et al.
Publicado: (2023)

Editorial: Emerging talents in cancer immunity and immunotherapy: 2022
por: Maeurer, Markus
Publicado: (2023)

Editorial: Translation of genetically engineered T cells in cancer immunotherapy
por: Voss, Ralf-Holger, et al.
Publicado: (2023)

Editorial: Dual role of inflammatory mediators in cancer immunotherapy
por: Wang, Xiaoli, et al.
Publicado: (2023)

Editorial: Rising stars in cancer immunity and immunotherapy 2022
por: Goyvaerts, Cleo, et al.
Publicado: (2023)

Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S
por: Theron, Michel, et al.
Publicado: (2017)

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

Research into the characteristic molecules significantly affecting liver cancer immunotherapy
por: Chen, Junhong, et al.
Publicado: (2023)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

Editorial: Translational phenomics and its applications in immunotherapy
por: Fang, Hai, et al.
Publicado: (2023)

Editorial: NK cells in viral immunology and immunotherapy
por: Mulik, Sachin, et al.
Publicado: (2023)

Editorial: Adhesion molecules and autoimmune diseases
por: Fan, Zhichao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ppjm48p56qo0s35lb4h1k3a2h8